Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:43 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 506197 | NSE: BLISSGVS

Bliss GVS Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹157.78Overvalued by 31.10%vs CMP ₹229.00

P/E (22.0) × ROE (8.4%) × BV (₹107.00) × DY (0.22%)

₹156.19Overvalued by 31.79%vs CMP ₹229.00
MoS: -46.6% (Negative)Confidence: 58/100 (Moderate)Models: 1 Under, 1 Fair, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹233.6723%Fair (+2%)
Graham NumberEarnings₹157.7017%Over (-31.1%)
Earnings PowerEarnings₹59.9611%Over (-73.8%)
DCFCash Flow₹259.0011%Under (+13.1%)
Net Asset ValueAssets₹106.907%Over (-53.3%)
EV/EBITDAEnterprise₹112.859%Over (-50.7%)
Earnings YieldEarnings₹103.307%Over (-54.9%)
ROCE CapitalReturns₹116.947%Over (-48.9%)
Revenue MultipleRevenue₹76.436%Over (-66.6%)
Consensus (9 models)₹156.19100%Overvalued
Key Drivers: EPS CAGR 48.1% lifts DCF — verify sustainability. | Wide model spread (₹60–₹259) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 48.1%

*Investments are subject to market risks

Investment Snapshot

59
Bliss GVS Pharma Ltd scores 59/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health66/100 · Strong
ROCE 11.7% AverageROE 8.4% AverageD/E 0.12 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 1.36% (6mo) AccumulatingDII holding down 0.77% MF sellingPromoter holding at 35.4% Stable
Earnings Quality40/100 · Moderate
OPM stable around 18% SteadyWorking capital: 199 days Capital intensive
Quarterly Momentum70/100 · Strong
Revenue (4Q): +7% YoY GrowingProfit (4Q): +61% YoY StrongOPM: 13.0% (down 6.0% YoY) Margin pressure
Industry Rank60/100 · Moderate
P/E 22.0 vs industry 53.8 Cheaper than peersROCE 11.7% vs industry 16.4% Average3Y sales CAGR: 3% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:43 am

Market Cap 2,427 Cr.
Current Price 229
Intrinsic Value₹156.19
High / Low 244/105
Stock P/E22.0
Book Value 107
Dividend Yield0.22 %
ROCE11.7 %
ROE8.36 %
Face Value 1.00
PEG Ratio0.46

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Bliss GVS Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Bliss GVS Pharma Ltd 2,427 Cr. 229 244/10522.0 1070.22 %11.7 %8.36 % 1.00
Dishman Carbogen Amcis Ltd 2,291 Cr. 146 322/12817.4 4060.00 %2.42 %0.32 % 2.00
IOL Chemicals & Pharmaceuticals Ltd 2,273 Cr. 77.4 127/57.518.2 59.71.29 %8.86 %6.13 % 2.00
Orchid Pharma Ltd 2,634 Cr. 519 899/471101 2510.00 %8.07 %8.21 % 10.0
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Bliss GVS Pharma Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 172206185160212201198184218210198207244
Expenses 148158179135158157170149176181177166213
Operating Profit 2548624544428344130214132
OPM % 14%23%3%15%26%22%14%19%19%14%11%20%13%
Other Income 2635135-244515123520
Interest 2151122241253
Depreciation 5556677778888
Profit before tax 2047-1225940-4303636236341
Tax % 21%37%-561%34%27%27%24%26%28%29%29%30%30%
Net Profit 16303144329-5222626174429
EPS in Rs 1.332.680.321.414.052.64-0.871.972.312.261.474.082.58

Last Updated: January 2, 2026, 5:32 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 23, 2026, 3:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 345407547798815899689577747752770810868
Expenses 273304391596618739566471629634620683727
Operating Profit 71103156203197160123107118117151127141
OPM % 21%25%29%25%24%18%18%18%16%16%20%16%16%
Other Income 28202412-8352620-4218-03672
Interest 18161920234865107812
Depreciation 1111132021913171719262933
Profit before tax 719614817514518212910454106117126168
Tax % 42%36%32%36%39%30%26%29%57%28%30%28%
Net Profit 416110011389127957423778290114
EPS in Rs 3.975.818.007.955.7011.999.436.641.456.807.218.0010.33
Dividend Payout % 13%12%6%8%18%8%5%8%34%7%7%6%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)48.78%63.93%13.00%-21.24%42.70%-25.20%-22.11%-68.92%234.78%6.49%9.76%
Change in YoY Net Profit Growth (%)0.00%15.15%-50.93%-34.24%63.94%-67.89%3.09%-46.81%303.70%-228.29%3.26%

Bliss GVS Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:7%
5 Years:3%
3 Years:3%
TTM:5%
Compounded Profit Growth
10 Years:3%
5 Years:-5%
3 Years:44%
TTM:4%
Stock Price CAGR
10 Years:0%
5 Years:1%
3 Years:24%
1 Year:22%
Return on Equity
10 Years:12%
5 Years:8%
3 Years:9%
Last Year:8%

Last Updated: September 5, 2025, 1:05 am

Balance Sheet

Last Updated: December 4, 2025, 1:03 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 10101010101010101010101111
Reserves 2773274024765266367257988088739571,0401,122
Borrowings 1731601322251181021261221091021008852
Other Liabilities 123166218311206157168147181171145162215
Total Liabilities 5836627621,0238609051,0301,0771,1091,1571,2121,3011,400
Fixed Assets 213234225305143146242234281379370406392
CWIP 40940470222382139
Investments 00000000284410
Other Assets 365428527714717712788840803768830870959
Total Assets 5836627621,0238609051,0301,0771,1091,1571,2121,3011,400

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 41381132891840476413534103106
Cash from Investing Activity + -11-29-50-24948-79-40-45-103-6-83-75
Cash from Financing Activity + -8-42-40-10-7617-6-21-24-25-21-30
Net Cash Flow 22-342330-10-220-293-10
Free Cash Flow 255101186-72-125563-597533
CFO/OP 106%45%101%160%29%-8%69%87%143%67%91%113%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-102.00-57.0024.00-22.0079.0058.00-3.00-15.009.0015.0051.0039.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 228222201116134187290293192187192198
Inventory Days 7069555055466411011694113111
Days Payable 1761651531005547758286795863
Cash Conversion Cycle 12112610267134186279321221202247246
Working Capital Days 8610584-10135154232264179192207199
ROCE %20%23%31%29%27%26%18%12%14%12%14%12%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 35.04%35.12%35.06%34.97%34.97%34.90%34.82%35.10%35.29%35.44%35.39%35.36%
FIIs 16.60%16.50%16.31%15.35%14.74%13.24%12.13%13.51%13.18%12.65%13.27%14.54%
DIIs 6.63%6.62%6.61%6.60%6.59%6.58%6.56%6.55%6.55%6.54%5.98%5.78%
Public 41.73%41.73%42.00%43.08%43.71%45.27%46.49%44.84%44.98%45.37%45.36%44.32%
No. of Shareholders 43,04142,18243,23440,75845,15744,73752,93749,55849,51746,70744,46143,380

Shareholding Pattern Chart

No. of Shareholders

Bliss GVS Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF 669 0.07 0.016692025-04-22 17:25:400%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 8.027.236.831.466.64
Diluted EPS (Rs.) 7.957.116.721.436.49
Cash EPS (Rs.) 11.3610.319.163.908.84
Book Value[Excl.RevalReserv]/Share (Rs.) 99.6895.8088.0881.6480.27
Book Value[Incl.RevalReserv]/Share (Rs.) 99.6895.8088.0881.6480.27
Revenue From Operations / Share (Rs.) 76.8573.5772.1672.0955.96
PBDIT / Share (Rs.) 15.4917.1312.9714.4512.30
PBIT / Share (Rs.) 12.6914.6111.1812.7810.63
PBT / Share (Rs.) 11.9211.1610.185.2210.10
Net Profit / Share (Rs.) 8.577.797.372.237.17
NP After MI And SOA / Share (Rs.) 8.007.216.801.456.64
PBDIT Margin (%) 20.1523.2817.9720.0421.98
PBIT Margin (%) 16.5119.8615.4917.7218.99
PBT Margin (%) 15.5115.1714.117.2418.03
Net Profit Margin (%) 11.1410.5910.203.0912.81
NP After MI And SOA Margin (%) 10.419.799.422.0111.86
Return on Networth / Equity (%) 8.027.808.011.838.47
Return on Capital Employeed (%) 11.8414.5112.0815.1312.55
Return On Assets (%) 6.486.216.121.356.36
Long Term Debt / Equity (X) 0.010.030.040.020.04
Total Debt / Equity (X) 0.060.090.110.120.12
Asset Turnover Ratio (%) 0.640.640.530.590.47
Current Ratio (X) 4.815.083.613.333.76
Quick Ratio (X) 4.084.343.082.803.27
Inventory Turnover Ratio (X) 6.633.062.963.712.73
Dividend Payout Ratio (NP) (%) 6.226.907.3234.417.52
Dividend Payout Ratio (CP) (%) 4.615.115.7915.986.01
Earning Retention Ratio (%) 93.7893.1092.6865.5992.48
Cash Earning Retention Ratio (%) 95.3994.8994.2184.0293.99
Interest Coverage Ratio (X) 20.1025.9513.0431.6023.01
Interest Coverage Ratio (Post Tax) (X) 12.1217.038.4021.4014.42
Enterprise Value (Cr.) 1137.761087.33770.70752.99990.81
EV / Net Operating Revenue (X) 1.411.411.031.011.72
EV / EBITDA (X) 6.976.065.705.037.81
MarketCap / Net Operating Revenue (X) 1.531.530.981.071.76
Retention Ratios (%) 93.7793.0992.6765.5892.47
Price / BV (X) 1.181.220.830.971.26
Price / Net Operating Revenue (X) 1.531.530.981.071.76
EarningsYield 0.060.060.090.010.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Bliss GVS Pharma Ltd. is a Public Limited Listed company incorporated on 11/12/1984 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1984PLC034771 and registration number is 034771. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 667.20 Cr. and Equity Capital is Rs. 10.54 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals102, Hyde Park, Saki Vihar Road, Mumbai Maharashtra 400072Contact not found
Management
NamePosition Held
Mr. Nandkumar K ChodankarChairman & Ind.Director
Mr. Gagan Harsh SharmaManaging Director
Dr. Vibha Gagan SharmaWhole Time Director
Mrs. Shruti Vishal RaoWhole Time Director
Mr. Santosh L ParabIndependent Director
Ms. Shilpa BhatiaIndependent Woman Director

FAQ

What is the intrinsic value of Bliss GVS Pharma Ltd and is it undervalued?

As of 14 April 2026, Bliss GVS Pharma Ltd's intrinsic value is ₹156.19, which is 31.79% lower than the current market price of ₹229.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (8.36 %), book value (₹107), dividend yield (0.22 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Bliss GVS Pharma Ltd?

Bliss GVS Pharma Ltd is trading at ₹229.00 as of 14 April 2026, with a FY2026-2027 high of ₹244 and low of ₹105. The stock is currently near its 52-week high. Market cap stands at ₹2,427 Cr..

How does Bliss GVS Pharma Ltd's P/E ratio compare to its industry?

Bliss GVS Pharma Ltd has a P/E ratio of 22.0, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Bliss GVS Pharma Ltd financially healthy?

Key indicators for Bliss GVS Pharma Ltd: ROCE of 11.7 % is moderate. Dividend yield is 0.22 %.

Is Bliss GVS Pharma Ltd profitable and how is the profit trend?

Bliss GVS Pharma Ltd reported a net profit of ₹90 Cr in Mar 2025 on revenue of ₹810 Cr. Compared to ₹23 Cr in Mar 2022, the net profit shows an improving trend.

Does Bliss GVS Pharma Ltd pay dividends?

Bliss GVS Pharma Ltd has a dividend yield of 0.22 % at the current price of ₹229.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bliss GVS Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports